<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167281</url>
  </required_header>
  <id_info>
    <org_study_id>00058518</org_study_id>
    <nct_id>NCT03167281</nct_id>
  </id_info>
  <brief_title>Early Intrapleural TPA Instillation Versus Late</brief_title>
  <acronym>ELEVATE</acronym>
  <official_title>Early Intrapleural TPA Instillation Versus Late</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palmetto Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palmetto Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chest tubes are used for air or fluid removal from the pleural space. When a chest tube is
      placed, it can be hard for the fluid to drain.Tissue plasminogen activator (tPA) and DNase
      are given through the chest tube to help with draining the fluid. We are doing this research
      to see if early addition of tPA-DNase immediately after chest tube placement will help with
      better fluid draining.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the timing and efficacy of early administration and
      late administration of t-PA/DNase via thoracostomy (n=60). Patients will be identified from
      the Intensive Care Unit, Coronary Care Unit, and wards/stepdown units. Prior to chest tube
      placement, patients will be randomized to one of the two treatment arms (early use of
      t-PA-DNase verus late use of t-PA-DNase). Route of administration will be via their
      thoracostomy tube over a period of three days twice daily.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Anticipated">February 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 16, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chest tube removal</measure>
    <time_frame>7 days</time_frame>
    <description>Time to chest tube removal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluid drainage</measure>
    <time_frame>3 days</time_frame>
    <description>Volume of fluid drained after each tPA and DNase instillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for other interventions</measure>
    <time_frame>4 days</time_frame>
    <description>Post tPA/DNase administration, the need for other interventions, such as surgery or additional chest tube, will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge</measure>
    <time_frame>3 weeks</time_frame>
    <description>Time to discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Tissue Plasminogen Activator</condition>
  <arm_group>
    <arm_group_label>tPA and DNase</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily 24-48 hours after chest tube placed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early tPA and DNase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily with initial administration occurring at chest tube placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>early tPA and DNase</intervention_name>
    <description>Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.</description>
    <arm_group_label>Early tPA and DNase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, age 18 years or older

          -  Patients with an indication for a thoracostomy tube placement for a pleural effusion

        Exclusion Criteria:

          -  Patients that require a thoracostomy tube for a pneumothorax

          -  Pregnant women

          -  Sensitivity to t-PA, or DNase

          -  Patients taking carbamazepine or nitroglycerin

          -  Lung volume reduction surgery on side of pleural effusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rohan Mankikar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palmetto Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rohan Mankikar, MD</last_name>
    <phone>803-799-5022</phone>
    <email>rohan.mankikar@palmettohealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rohan Arya, MD</last_name>
    <phone>803-799-5022</phone>
    <email>rohan.arya@uscmed.sc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Palmetto Health Richland</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://scresearch.org/studies/search?utf8=%E2%9C%93&amp;q=Mankikar&amp;commit=GO</url>
    <description>South Carolina Research Studies Directory</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Palmetto Health</investigator_affiliation>
    <investigator_full_name>Dr. Rohan Mankikar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chest tube</keyword>
  <keyword>Thoracostomy</keyword>
  <keyword>Pleural Diseases</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Pneumothorax</keyword>
  <keyword>Thoracic Surgery</keyword>
  <keyword>Deoxyribonucleases</keyword>
  <keyword>Fibrinolytic Agents</keyword>
  <keyword>Drainage</keyword>
  <keyword>Pleural Effusion</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

